TO: Records FROM: Robert Oldham SUBJECT: Sample Analyses Without Detailed Result Forms The following analyses on the sample indicated do not have Detailed Result Forms. Results were entered directly into CHEM FILE from the notebook containing the calculations using the CHEM coding Form, CHR-ANL-12/19/73. NUCLIDE ANALYZED SAMPLE ID LAB NO AM241 40-004.010 2980 " 40-004.EIC2 2986 " 40-009.19 946 " 40-009.20 947 " 40-009.22 to 40-0009.27 949 to 954 " 40-010.B51 1834 " 40-010.E14 1877 " 40-012.08 1147 " 40-012.10 1149 " 40-012.11 1150 " 40-012.13 1152 PU239 40-009.01 to 40-009.28 930 to 955 " 40-012.07 to 40-012.23 1146 TO 1162 PU238 40.001.BY1 3006 " 40-003.04 1130 " 40-003.11 1137 " 40-003.12 1138 cc: J. Plondke R. Oldham DETAILED RESULTS: 40-004 AOD2 PU239 (NEW) 811109 9PU 700663 NAME: *Case No.: 40-004 *SAMPLE NO.: AOD2 EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2981 TYPE: BO SAMPLE DESCRIPTION: FRONTAL SEE B TOOHEY Item Unit --------ANALYSIS NUMBER--------- 1 2 3 1. SAMPLE SUB-NUMBER AOD2B AOD2C AOD2D 2. METHOD CRI CRI CRI 3. DATE REQUESTED 770812 770812 770812 4. DATE ANALYZED GMA 790123 790206 7903080 5. SAMPLE SIZE 123.480 123.480 123.480 6. ALIQUOT (FRACTION) 0.001 0.001 0.002 7. SAMPLE SIZE MEASURED GMA 0.126 0.170 0.188 8. 242 PU SPIKE DON 37.400 37.400 37.400 9. STD. ERROR OF ITEM 8 CTS 0.130 0.130 0.130 10. 242 PU SAMPLE COUNTS PCI 13928 20540 53121 11. 239 PU SAMPLE COUNTS PCI 2459 4962 13932 12. 239 PU IN SAMPLE PCI 2.975 4.070 4.419 13. STD. ERROR (COUNTS+SYS) PCI 6.588E-Q2 6.592E-Q2 4.478E-Q2 14. CONCENTRATION 239 PU PCI/GMA 23.618 23.886 23,544 15. STD. ERROR (CNT+SYS) PCI/GMA 0.523 0.387 0.239 16. REFERNCES-CHR DOCS. R112RO R112RO R112RO *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 23.635 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.101 PCI/GMA 3. STD. ERROR (INTERNAL) 0.189 PCI/GMA 4. VARIANCE RATION.F 0.285 5. FRACTIONAL STD. ERROR 0.0080 6. PU (MEAN) IN ALIQU #1 2.977 0.024 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 23.658 0.189 PCI/GMA ANALYZED BY:RD CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ DETAILED RESULTS: 40-004 C10 PU239 (NEW) 811109 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2979 TYPE: BO SAMPLE DESCRIPTION: VERT1CERV Item Unit --------ANALYSIS NUMBER--------- 1 2 1. SAMPLE SUB-NUMBER C10C C10D 2. METHOD CRI CRI 3. DATE REQUESTED 770812 770812 4. DATE ANALYZED GMA 790206 790308 5. SAMPLE SIZE 7.777 7.777 6. ALIQUOT (FRACTION) 0.020 0.022 7. SAMPLE SIZE MEASURED GMA 0.155 0.168 8. 242 PU SPIKE DON 37.400 37.400 9. STD. ERROR OF ITEM 8 CTS 0.130 0.130 10. 242 PU SAMPLE COUNTS PCI 21620 54458 11. 239 PU SAMPLE COUNTS PCI 8224 20876 12. 239 PU IN SAMPLE PCI 6.409 6,459 13. STD. ERROR (COUNTS+SYS) PCI 8.597e-02 5.717e-02 14. CONCENTRATION 239 PU PCI/GMA 41.373 38.380 15. STD. ERROR (CNT+SYS) PCI/GMA 0.555 0.340 16. REFERNCES-CHR DOCS. R112RO R112RO *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 39.196 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.333 PCI/GMA 3. STD. ERROR (INTERNAL) 0.290 PCI/GMA 4. VARIANCE RATION.F 0.154 5. FRACTIONAL STD. ERROR 0.0340 6. PU (MEAN) IN ALIQU #1 6.072 0.206 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 39.233 0.334 PCI/GMA ANALYZED BY:RD CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 EODC PU239 (NEW) 811 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 3401 TYPE: BO SAMPLE DESCRIPTION: HUNRTDIST CORT PORTION OF EOD2 Item Unit --------ANALYSIS NUMBER--------- 1 1. SAMPLE SUB-NUMBER EDODCA 2. METHOD CRI 3. DATE REQUESTED 781208 4. DATE ANALYZED GMA 790221 5. SAMPLE SIZE 3.016 6. ALIQUOT (FRACTION) 0.069 7. SAMPLE SIZE MEASURED GMA 0.209 8. 242 PU SPIKE DON 37.400 9. STD. ERROR OF ITEM 8 CTS 0.130 10. 242 PU SAMPLE COUNTS PCI 46559 11. 239 PU SAMPLE COUNTS PCI 7078 12. 239 PU IN SAMPLE PCI 2.561 13. STD. ERROR (COUNTS+SYS) PCI 3.387e-02 14. CONCENTRATION 239 PU PCI/GMA 12.271 15. STD. ERROR (CNT+SYS) PCI/GMA 0.162 16. REFERNCES-CHR DOCS. R112RO *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 12.271 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.000 PCI/GMA 3. STD. ERROR (INTERNAL) 0.162 PCI/GMA 4. VARIANCE RATION.F 0.000 5. FRACTIONAL STD. ERROR 0.0132 6. PU (MEAN) IN ALIQU #1 2.561 0.034 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 12.283 0.162 PCI/GMA ANALYZED BY:RD CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 EODC PU239 (NEW) 811 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 3402 TYPE: BO SAMPLE DESCRIPTION: HUMRTDIST MIX OF TRAB CORT OF EOD2 Item Unit --------ANALYSIS NUMBER--------- 1 1. SAMPLE SUB-NUMBER EDODCA 2. METHOD CRI 3. DATE REQUESTED 781208 4. DATE ANALYZED GMA 790228 5. SAMPLE SIZE 0.406 6. ALIQUOT (FRACTION) 0.400 7. SAMPLE SIZE MEASURED GMA 0.162 8. 242 PU SPIKE DON 37.400 9. STD. ERROR OF ITEM 8 CTS 0.130 10. 242 PU SAMPLE COUNTS PCI 48146 11. 239 PU SAMPLE COUNTS PCI 11188 12. 239 PU IN SAMPLE PCI 3.915 13. STD. ERROR (COUNTS+SYS) PCI 4.329E-02 14. CONCENTRATION 239 PU PCI/GMA 24.115 15. STD. ERROR (CNT+SYS) PCI/GMA 0.267 16. REFERNCES-CHR DOCS. R112RO *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 24.115 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.000 PCI/GMA 3. STD. ERROR (INTERNAL) 0.267 PCI/GMA 4. VARIANCE RATION.F 0.000 5. FRACTIONAL STD. ERROR 0.0111 6. PU (MEAN) IN ALIQU #1 3.915 0.043 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 24.137 0.267 PCI/GMA ANALYZED BY:RD CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 EODC PU239 (NEW) 811 239PU (PLUTONIUM) 700664 NAME: *Case No.: 40-004 *SAMPLE NO.: EO EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 3403 TYPE: BO SAMPLE DESCRIPTION: HUMRTDIST TRAB PORTION OF EOD2 Item Unit --------ANALYSIS NUMBER--------- 1 1. SAMPLE SUB-NUMBER EDODCA 2. METHOD CRI 3. DATE REQUESTED 781208 4. DATE ANALYZED GMA 790226 5. SAMPLE SIZE 9.320E-02 6. ALIQUOT (FRACTION) 0.400 7. SAMPLE SIZE MEASURED GMA 3.723E-02 8. 242 PU SPIKE DON 37.400 9. STD. ERROR OF ITEM 8 CTS 0.130 10. 242 PU SAMPLE COUNTS PCI 65755 11. 239 PU SAMPLE COUNTS PCI 9407 12. 239 PU IN SAMPLE PCI 2.410 13. STD. ERROR (COUNTS+SYS) PCI 2.786E-02 14. CONCENTRATION 239 PU PCI/GMA 64.656 15. STD. ERROR (CNT+SYS) PCI/GMA 0.747 16. REFERNCES-CHR DOCS. R112RO *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 64.656 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.000 PCI/GMA 3. STD. ERROR (INTERNAL) 0.747 PCI/GMA 4. VARIANCE RATION.F 0.000 5. FRACTIONAL STD. ERROR 0.0116 6. PU (MEAN) IN ALIQU #1 2.410 0.028 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 64.718 0.748 PCI/GMA ANALYZED BY:RD CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 EODC PU239 (NEW) 780922 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2985 TYPE: BO SAMPLE DESCRIPTION: HUMRTDIST Item Unit --------ANALYSIS NUMBER--------- 1 1. SAMPLE SUB-NUMBER EDODCA 2. METHOD CRI 3. DATE REQUESTED 770812 4. DATE ANALYZED GMA 780522 5. SAMPLE SIZE 0.198 6. ALIQUOT (FRACTION) 1.000 7. SAMPLE SIZE MEASURED GMA 0.198 8. 242 PU SPIKE DON 42.740 9. STD. ERROR OF ITEM 8 CTS 0.380 10. 242 PU SAMPLE COUNTS PCI 37215 11. 239 PU SAMPLE COUNTS PCI 6844 12. 239 PU IN SAMPLE PCI 3.541 13. STD. ERROR (COUNTS+SYS) PCI 5.621E-02 14. CONCENTRATION 239 PU PCI/GMA 17.848 15. STD. ERROR (CNT+SYS) PCI/GMA 0.283 16. REFERNCES-CHR DOCS. R 105C *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 17.848 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.000 PCI/GMA 3. STD. ERROR (INTERNAL) 0.283 PCI/GMA 4. VARIANCE RATION.F 0.000 5. FRACTIONAL STD. ERROR 0.0159 6. PU (MEAN) IN ALIQU #1 3.541 0.056 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 17.864 0.284 PCI/GMA ANALYZED BY:RD CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 C10 PU239 (NEW) 7807 CALCIUM 700665 NAME: *Case No.: 40-004 *SAMPLE NO.: E10 EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2986 TYPE: BO SAMPLE DESCRIPTION: HUMLTMS Item Unit --------ANALYSIS NUMBER--------- 1 2 1. SAMPLE SUB-NUMBER E1C2C E1C2C 2. METHOD CHA CHA 3. DATE REQUESTED 780414 780414 4. DATE ANALYZED 780630 780705 5. SAMPLE SIZE GMA 0.246 0.246 6. ALIQUOT (FRACTION) 0.200 0.200 7. VOL. OF ALIQUOT ML 25.000 25.000 8. VOL. MEASURED ML 0.025 0.025 9. ALIQUOT FACTOR 2.000E-04 2.000E-04 10. SAMPLE SIZE MEASURED GMA 4.914E-05 4.914e-05 11. CA IN ALIQUOT UG 15.100 14.900 12. STD. ERROR (SYS) - 2% UG 0.362 0.359 13. CA CONCN OR RATE MG/GMA 307.285 303.216 14. REFERENCES-CHR DOCS. RC30JS RC30JS *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 305.231 MG/GMA 2. STD. ERROR (EXTERNAL) 2.035 MG/GMA 3. STD. ERROR (INTERNAL) 5.188 MG/GMA 4. VARIANCE RATION.F 0.154 5. FRACTIONAL STD. ERROR 0.017 CA (MEAN) IN ALIQ #1: 14.999 + 0.255 UG CA CONCENTRATION OF RATE: 305.231 + 5.188 MG/GMA *ASH CONTENT OF BONE, (CA/ASH=0.387* ASH CONTENT 0.1938+ 0.0033(SE) GMA ASH/GMA 78.9% ANALYZED BY: PWU CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 3/7/75 (HFL) DETAILED RESULTS: 40-004 AOD2 PU239 (NEW) 78092 239PU (PLUTONIUM) 700666 NAME: *Case No.: 40-004 *SAMPLE NO.: EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2986 TYPE: BO SAMPLE DESCRIPTION: HUMLTMS Item Unit --------ANALYSIS NUMBER--------- 1 2 3 1. SAMPLE SUB-NUMBER E1C2A E1C2E E1C2D 2. METHOD CRI CRI CRI 3. DATE REQUESTED 770812 770812 770812 4. DATE ANALYZED GMA 780519 780729 780823 5. SAMPLE SIZE 0.106 0.501 0.518 6. ALIQUOT (FRACTION) 1.000 1.000 1.000 7. SAMPLE SIZE MEASURED GMA 0.106 0.501 0.518 8. 242 PU SPIKE DON 42.740 42.740 43.770 9. STD. ERROR OF ITEM 8 CTS 0.380 0.380 0.290 10. 242 PU SAMPLE COUNTS PCI 39124 25804 16352 11. 239 PU SAMPLE COUNTS PCI 3498 10852 6807 12. 239 PU IN SAMPLE PCI 1.721 8.098 8.208 13. STD. ERROR (COUNTS+SYS) PCI 3.402E-02 1.173E-01 1.303E-01 14. CONCENTRATION 239 PU PCI/GMA 16.317 16.169 15.840 15. STD. ERROR (CNT+SYS) PCI/GMA 0.322 0.234 0.251 16. REFERNCES-CHR DOCS. R 105C R111RW R111RO *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 16.083 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.135 PCI/GMA 3. STD. ERROR (INTERNAL) 0.151 PCI/GMA 4. VARIANCE RATION.F 0.799 5. FRACTIONAL STD. ERROR 0.0094 6. PU (MEAN) IN ALIQU #1 1.697 0.016 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 23.658 0.189 PCI/GMA ANALYZED BY:RD CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 DETAILED RESULTS: 40-004 EODC PU239 (NEW) 780922 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: E20 EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2987 TYPE: BO SAMPLE DESCRIPTION: RADRTMS Item Unit --------ANALYSIS NUMBER--------- 1 1. SAMPLE SUB-NUMBER E2C0 2. METHOD CRI 3. DATE REQUESTED 770812 4. DATE ANALYZED GMA 780524 5. SAMPLE SIZE 0.204 6. ALIQUOT (FRACTION) 1.000 7. SAMPLE SIZE MEASURED GMA 0.204 8. 242 PU SPIKE DON 42.740 9. STD. ERROR OF ITEM 8 CTS 0.380 10. 242 PU SAMPLE COUNTS PCI 27185 11. 239 PU SAMPLE COUNTS PCI 2740 12. 239 PU IN SAMPLE PCI 1.941 13. STD. ERROR (COUNTS+SYS) PCI 4.255E-02 14. CONCENTRATION 239 PU PCI/GMA 9.494 15. STD. ERROR (CNT+SYS) PCI/GMA 0.208 16. REFERNCES-CHR DOCS. R 105C *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 9.494 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.000 PCI/GMA 3. STD. ERROR (INTERNAL) 0.208 PCI/GMA 4. VARIANCE RATION.F 0.000 5. FRACTIONAL STD. ERROR 0.0219 6. PU (MEAN) IN ALIQU #1 1.941 0.043 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 9.503 0.208 PCI/GMA ANALYZED BY:RD CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 EODC PU239 (NEW) 780922 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2988 TYPE: BO SAMPLE DESCRIPTION: RADRTMS Item Unit --------ANALYSIS NUMBER--------- 1 1. SAMPLE SUB-NUMBER E3C0 2. METHOD CRI 3. DATE REQUESTED 770812 4. DATE ANALYZED GMA 780601 5. SAMPLE SIZE 0.201 6. ALIQUOT (FRACTION) 1.000 7. SAMPLE SIZE MEASURED GMA 0.201 8. 242 PU SPIKE DON 42.740 9. STD. ERROR OF ITEM 8 CTS 0.380 10. 242 PU SAMPLE COUNTS PCI 22498 11. 239 PU SAMPLE COUNTS PCI 1878 12. 239 PU IN SAMPLE PCI 1.607 13. STD. ERROR (COUNTS+SYS) PCI 4.116E-02 14. CONCENTRATION 239 PU PCI/GMA 8.004 15. STD. ERROR (CNT+SYS) PCI/GMA 0.205 16. REFERNCES-CHR DOCS. R 105C *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 8.004 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.000 PCI/GMA 3. STD. ERROR (INTERNAL) 0.205 PCI/GMA 4. VARIANCE RATION.F 0.000 5. FRACTIONAL STD. ERROR 0.0256 6. PU (MEAN) IN ALIQU #1 1.607 0.041 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 8.012 0.205 PCI/GMA ANALYZED BY:RD CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 C10 PU239 (NEW) 780712 CALCIUM 700667 NAME: *Case No.: 40-004 *SAMPLE NO.: E10 EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2982 TYPE: BO SAMPLE DESCRIPTION: FEMRTMET Item Unit --------ANALYSIS NUMBER--------- 1 2 1. SAMPLE SUB-NUMBER K4A6C E1C2C 2. METHOD CHA CHA 3. DATE REQUESTED 770812 780414 4. DATE ANALYZED 780630 780705 5. SAMPLE SIZE GMA 0.223 0.246 6. ALIQUOT (FRACTION) 0.200 0.200 7. VOL. OF ALIQUOT ML 25.000 25.000 8. VOL. MEASURED ML 0.025 0.025 9. ALIQUOT FACTOR 2.000E-04 2.000E-04 10. SAMPLE SIZE MEASURED GMA 4.464E-05 4.464E-05 11. CA IN ALIQUOT UG 16.000 16.100 12. STD. ERROR (SYS) - 2% UG 0.377 0.379 13. CA CONCN OR RATE MG/GMA 358.423 360.663 14. REFERENCES-CHR DOCS. RC30JS RC30JS *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 359.538 MG/GMA 2. STD. ERROR (EXTERNAL) 1.120 MG/GMA 3. STD. ERROR (INTERNAL) 5.991 MG/GMA 4. VARIANCE RATION.F 0.035 5. FRACTIONAL STD. ERROR 0.017 6. CA (MEAN) IN ALIQU #1 16.050 0.267 UG CA CONCENTRATION OR RATE: 359.538 5.991 MG/GMA *ASH CONTENT OF BONE, (CA/ASH=0.387)* ASH CONTENT 0.2074+ 0.0035(SE) GMA ASH/GMA 92.9% ANALYZED BY: PWU CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 3/7/75 (HFL) DETAILED RESULTS: 40-004 C10 PU239 (NEW) 7809 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2982 TYPE: BO SAMPLE DESCRIPTION: FEMRTMET Item Unit --------ANALYSIS NUMBER--------- 1 2 1. SAMPLE SUB-NUMBER K4A6A K4A6B 2. METHOD CRI CRI 3. DATE REQUESTED 770812 770812 4. DATE ANALYZED GMA 770829 770906 5. SAMPLE SIZE 0.108 0.101 6. ALIQUOT (FRACTION) 0.080 1.000 7. SAMPLE SIZE MEASURED GMA 8.656E-03 1.005E-01 8. 242 PU SPIKE DON 51.620 47.800 9. STD. ERROR OF ITEM 8 CTS 0.270 0.250 10. 242 PU SAMPLE COUNTS PCI 63191 35539 11. 239 PU SAMPLE COUNTS PCI 1119 7705 12. 239 PU IN SAMPLE PCI 0.412 4.669 13. STD. ERROR (COUNTS+SYS) PCI 1.260E-02 6.355E-02 14. CONCENTRATION 239 PU PCI/GMA 47.574 46.454 15. STD. ERROR (CNT+SYS) PCI/GMA 1.456 0.632 16. REFERNCES-CHR DOCS. R 103C R 103C *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 46.632 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.409 PCI/GMA 3. STD. ERROR (INTERNAL) 0.580 PCI/GMA 4. VARIANCE RATION.F 0.498 5. FRACTIONAL STD. ERROR 0.0124 6. PU (MEAN) IN ALIQU #1 0.494 + 0.005 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 46.674 + 0.581 PCI/GMA ANALYZED BY:CGC CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 EODC PU239 (NEW) 780922 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: RH EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2983 TYPE: BO SAMPLE DESCRIPTION: FEMRTPMT Item Unit --------ANALYSIS NUMBER--------- 1 1. SAMPLE SUB-NUMBER K4B1 2. METHOD CRI 3. DATE REQUESTED 770812 4. DATE ANALYZED GMA 780517 5. SAMPLE SIZE 0.351 6. ALIQUOT (FRACTION) 0.120 7. SAMPLE SIZE MEASURED GMA 4.212E-02 8. 242 PU SPIKE DON 42.740 9. STD. ERROR OF ITEM 8 CTS 0.380 10. 242 PU SAMPLE COUNTS PCI 33461 11. 239 PU SAMPLE COUNTS PCI 1143 12. 239 PU IN SAMPLE PCI 0.658 13. STD. ERROR (COUNTS+SYS) PCI 2.063E-02 14. CONCENTRATION 239 PU PCI/GMA 15.615 15. STD. ERROR (CNT+SYS) PCI/GMA 0.490 16. REFERNCES-CHR DOCS. R 105C *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 15.615 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.000 PCI/GMA 3. STD. ERROR (INTERNAL) 0.490 PCI/GMA 4. VARIANCE RATION.F 0.000 5. FRACTIONAL STD. ERROR 0.0314 6. PU (MEAN) IN ALIQU #1 0.658 0.021 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 15.630 0.490 PCI/GMA ANALYZED BY:CGC CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 C10 PU239 (NEW) 81110 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: K4 EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2984 TYPE: BO SAMPLE DESCRIPTION: FEMRTMET Item Unit --------ANALYSIS NUMBER--------- 1 2 1. SAMPLE SUB-NUMBER K4C3B K4C3C 2. METHOD CRI CRI 3. DATE REQUESTED 770812 770812 4. DATE ANALYZED GMA 790207 790312 5. SAMPLE SIZE 21.884 21.884 6. ALIQUOT (FRACTION) 0.010 0.009 7. SAMPLE SIZE MEASURED GMA 37.400 37.400 8. 242 PU SPIKE DON 0.130 0.130 9. STD. ERROR OF ITEM 8 CTS 35222 35310 10. 242 PU SAMPLE COUNTS PCI 7455 6819 11. 239 PU SAMPLE COUNTS PCI 3.566 3.254 12. 239 PU IN SAMPLE PCI 4.712E-02 4.450E-02 13. STD. ERROR (COUNTS+SYS) PCI 15.579 15.684 14. CONCENTRATION 239 PU PCI/GMA 0.206 0.215 15. STD. ERROR (CNT+SYS) PCI/GMA 1.456 0.632 16. REFERNCES-CHR DOCS. R112RO R112RO *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 15.629 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.052 PCI/GMA 3. STD. ERROR (INTERNAL) 0.149 PCI/GMA 4. VARIANCE RATION.F 0.124 5. FRACTIONAL STD. ERROR 0.0095 6. PU (MEAN) IN ALIQU #1 3.578 + 0.034 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 15.644 + 0.149 PCI/GMA ANALYZED BY:CGC CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 EODC PU239 (NEW) 780922 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: K5 EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2989 TYPE: BO SAMPLE DESCRIPTION: FEMRTPMT Item Unit --------ANALYSIS NUMBER--------- 1 1. SAMPLE SUB-NUMBER K5BO 2. METHOD CRI 3. DATE REQUESTED 770812 4. DATE ANALYZED GMA 780518 5. SAMPLE SIZE 0.250 6. ALIQUOT (FRACTION) 0.120 7. SAMPLE SIZE MEASURED GMA 3.001E-02 8. 242 PU SPIKE DON 42.740 9. STD. ERROR OF ITEM 8 CTS 0.380 10. 242 PU SAMPLE COUNTS PCI 33118 11. 239 PU SAMPLE COUNTS PCI 852 12. 239 PU IN SAMPLE PCI 0.454 13. STD. ERROR (COUNTS+SYS) PCI 1.625E-02 14. CONCENTRATION 239 PU PCI/GMA 15.134 15. STD. ERROR (CNT+SYS) PCI/GMA 0.542 16. REFERNCES-CHR DOCS. R 105C *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 15.134 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.000 PCI/GMA 3. STD. ERROR (INTERNAL) 0.542 PCI/GMA 4. VARIANCE RATION.F 0.000 5. FRACTIONAL STD. ERROR 0.0358 6. PU (MEAN) IN ALIQU #1 0.454 0.016 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 15.148 0.542 PCI/GMA ANALYZED BY:CGC CHECK ED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 EODC PU239 (NEW) 780922 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2990 TYPE: BO SAMPLE DESCRIPTION: TIBRTPMT Item Unit --------ANALYSIS NUMBER--------- 1 1. SAMPLE SUB-NUMBER K65BO 2. METHOD CRI 3. DATE REQUESTED 770812 4. DATE ANALYZED GMA 780524 5. SAMPLE SIZE 0.156 6. ALIQUOT (FRACTION) 1.0000 7. SAMPLE SIZE MEASURED GMA 0.156 8. 242 PU SPIKE DON 42.740 9. STD. ERROR OF ITEM 8 CTS 0.380 10. 242 PU SAMPLE COUNTS PCI 13398 11. 239 PU SAMPLE COUNTS PCI 1070 12. 239 PU IN SAMPLE PCI 1.538 13. STD. ERROR (COUNTS+SYS) PCI 5.073E-02 14. CONCENTRATION 239 PU PCI/GMA 9.882 15. STD. ERROR (CNT+SYS) PCI/GMA 0.326 16. REFERNCES-CHR DOCS. R 105C *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 9.882 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.000 PCI/GMA 3. STD. ERROR (INTERNAL) 0.326 PCI/GMA 4. VARIANCE RATION.F 0.000 5. FRACTIONAL STD. ERROR 0.0330 6. PU (MEAN) IN ALIQU #1 1.538 0.051 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 9.892 + 0.326 PCI/GMA ANALYZED BY:CGC CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 EODC PU239 (NEW) 780922 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: K7 EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2991 TYPE: BO SAMPLE DESCRIPTION: TIBRTPMT Item Unit --------ANALYSIS NUMBER--------- 1 1. SAMPLE SUB-NUMBER K65BO 2. METHOD CRI 3. DATE REQUESTED 770812 4. DATE ANALYZED GMA 780524 5. SAMPLE SIZE 0.200 6. ALIQUOT (FRACTION) 1.000 7. SAMPLE SIZE MEASURED GMA 0.200 8. 242 PU SPIKE DON 42.740 9. STD. ERROR OF ITEM 8 CTS 0.380 10. 242 PU SAMPLE COUNTS PCI 45837 11. 239 PU SAMPLE COUNTS PCI 5222 12. 239 PU IN SAMPLE PCI 2.194 13. STD. ERROR (COUNTS+SYS) PCI 3.751E-02 14. CONCENTRATION 239 PU PCI/GMA 10.968 15. STD. ERROR (CNT+SYS) PCI/GMA 0.188 16. REFERNCES-CHR DOCS. R 105C *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 10.968 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.000 PCI/GMA 3. STD. ERROR (INTERNAL) 0.188 PCI/GMA 4. VARIANCE RATION.F 0.000 5. FRACTIONAL STD. ERROR 0.0171 6. PU (MEAN) IN ALIQU #1 2.194 0.038 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 10.978 + 0.038 PCI/GMA ANALYZED BY:CGC CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 EODC PU239 (NEW) 780922 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2992 TYPE: BO SAMPLE DESCRIPTION: TAKYSLT Item Unit --------ANALYSIS NUMBER--------- 1 1. SAMPLE SUB-NUMBER L31 2. METHOD CRI 3. DATE REQUESTED 770812 4. DATE ANALYZED GMA 780525 5. SAMPLE SIZE 0.149 6. ALIQUOT (FRACTION) 1.000 7. SAMPLE SIZE MEASURED GMA 0.149 8. 242 PU SPIKE DON 42.740 9. STD. ERROR OF ITEM 8 CTS 0.380 10. 242 PU SAMPLE COUNTS PCI 40489 11. 239 PU SAMPLE COUNTS PCI 3649 12. 239 PU IN SAMPLE PCI 1.735 13. STD. ERROR (COUNTS+SYS) PCI 3.373E-02 14. CONCENTRATION 239 PU PCI/GMA 11.670 15. STD. ERROR (CNT+SYS) PCI/GMA 0.227 16. REFERNCES-CHR DOCS. R 105C *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 11.670 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.000 PCI/GMA 3. STD. ERROR (INTERNAL) 0.227 PCI/GMA 4. VARIANCE RATION.F 0.000 5. FRACTIONAL STD. ERROR 0.0194 6. PU (MEAN) IN ALIQU #1 1.735 0.034 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 11.680 + 0.227 PCI/GMA ANALYZED BY:CGC CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 EODC PU239 (NEW) 8111 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: Q EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 3687 TYPE: BO SAMPLE DESCRIPTION: VERT4THBO CORT PORTION OF Q5A1 Item Unit --------ANALYSIS NUMBER--------- 1 1. SAMPLE SUB-NUMBER Q5ACA 2. METHOD CRI 3. DATE REQUESTED 790515 4. DATE ANALYZED GMA 790622 5. SAMPLE SIZE 0.404 6. ALIQUOT (FRACTION) 1.040 7. SAMPLE SIZE MEASURED GMA 1.617E-02 8. 242 PU SPIKE DON 35.400 9. STD. ERROR OF ITEM 8 CTS 0.130 10. 242 PU SAMPLE COUNTS PCI 16380 11. 239 PU SAMPLE COUNTS PCI 1696 12. 239 PU IN SAMPLE PCI 1.745 13. STD. ERROR (COUNTS+SYS) PCI 4.491E-02 14. CONCENTRATION 239 PU PCI/GMA 107.900 15. STD. ERROR (CNT+SYS) PCI/GMA 2.778 16. REFERNCES-CHR DOCS. R121RO *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 107.900 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.000 PCI/GMA 3. STD. ERROR (INTERNAL) 2.778 PCI/GMA 4. VARIANCE RATION.F 0.000 5. FRACTIONAL STD. ERROR 0.0257 6. PU (MEAN) IN ALIQU #1 1.745 0.045 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 108.004 + 2.780 PCI/GMA ANALYZED BY:SMM CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 EODC PU239 (NEW) 81110 239PU (PLUTONIUM) 700670 NAME: *Case No.: 40-004 *SAMPLE NO.: Q5 EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 3688 TYPE: BO SAMPLE DESCRIPTION: VERT4THBO MIX OF CORT + TRAB OF Q5A1 Item Unit --------ANALYSIS NUMBER--------- 1 1. SAMPLE SUB-NUMBER Q5AIA 2. METHOD CRI 3. DATE REQUESTED 790515 4. DATE ANALYZED GMA 790622 5. SAMPLE SIZE 1.127 6. ALIQUOT (FRACTION) 1.010 7. SAMPLE SIZE MEASURED GMA 1.127E-02 8. 242 PU SPIKE DON 37.400 9. STD. ERROR OF ITEM 8 CTS 0.130 10. 242 PU SAMPLE COUNTS PCI 15608 11. 239 PU SAMPLE COUNTS PCI 2172 12. 239 PU IN SAMPLE PCI 2.345 13. STD. ERROR (COUNTS+SYS) PCI 5.431E-02 14. CONCENTRATION 239 PU PCI/GMA 208.044 15. STD. ERROR (CNT+SYS) PCI/GMA 4.819 16. REFERNCES-CHR DOCS. R121RO *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 2-8.044 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.000 PCI/GMA 3. STD. ERROR (INTERNAL) 4.819 PCI/GMA 4. VARIANCE RATION.F 0.000 5. FRACTIONAL STD. ERROR 0.0232 6. PU (MEAN) IN ALIQU #1 2.345 0.054 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 208.244 + 4.824 PCI/GMA ANALYZED BY:SMM CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 EODC PU239 (NEW) 811109 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: Q5A EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 3689 TYPE: BO SAMPLE DESCRIPTION: VERT4THBO TRAB PORTION OF Q5A1 Item Unit --------ANALYSIS NUMBER--------- 1 1. SAMPLE SUB-NUMBER Q5ATA 2. METHOD CRI 3. DATE REQUESTED 790515 4. DATE ANALYZED GMA 790622 5. SAMPLE SIZE 0.236 6. ALIQUOT (FRACTION) 0.040 7. SAMPLE SIZE MEASURED GMA 9.452E-03 8. 242 PU SPIKE DON 37.400 9. STD. ERROR OF ITEM 8 CTS 0.130 10. 242 PU SAMPLE COUNTS PCI 12741 11. 239 PU SAMPLE COUNTS PCI 1680 12. 239 PU IN SAMPLE PCI 2.222 13. STD. ERROR (COUNTS+SYS) PCI 5.818E-02 14. CONCENTRATION 239 PU PCI/GMA 235.043 15. STD. ERROR (CNT+SYS) PCI/GMA 6.155 16. REFERNCES-CHR DOCS. R121RO *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 235.043 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.000 PCI/GMA 3. STD. ERROR (INTERNAL) 6.155 PCI/GMA 4. VARIANCE RATION.F 0.000 5. FRACTIONAL STD. ERROR 0.0262 6. PU (MEAN) IN ALIQU #1 2.222 0.058 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 235.269 + 6.161 PCI/GMA ANALYZED BY:SMM CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) DETAILED RESULTS: 40-004 C10 PU239 (NEW) 780712 CALCIUM 700671 NAME: *Case No.: 40-004 *SAMPLE NO.: E10 EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2980 TYPE: BO SAMPLE DESCRIPTION: RIB Item Unit --------ANALYSIS NUMBER--------- 1 2 1. SAMPLE SUB-NUMBER 010C 010C 2. METHOD CHA CHA 3. DATE REQUESTED 770812 780812 4. DATE ANALYZED 780630 780705 5. SAMPLE SIZE GMA 0.245 0.245 6. ALIQUOT (FRACTION) 0.200 0.200 7. VOL. OF ALIQUOT ML 25.000 25.000 8. VOL. MEASURED ML 0.025 0.025 9. ALIQUOT FACTOR 2.000E-04 2.000E-04 10. SAMPLE SIZE MEASURED GMA 4.464E-05 4.464E-05 11. CA IN ALIQUOT UG 16.900 17.300 12. STD. ERROR (SYS) - 2% UG 0.393 0.400 13. CA CONCN OR RATE MG/GMA 344.898 353.062 14. REFERENCES-CHR DOCS. RC30JS RC30JS *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 348.909 MG/GMA 2. STD. ERROR (EXTERNAL) 4.081 MG/GMA 3. STD. ERROR (INTERNAL) 5.717 MG/GMA 4. VARIANCE RATION.F 0.510 5. FRACTIONAL STD. ERROR 0.016 6. CA (MEAN) IN ALIQU #1 17.096 0.280 UG CA CONCENTRATION OR RATE: 348.909 5.717 MG/GMA *ASH CONTENT OF BONE, (CA/ASH=0.387)* ASH CONTENT 0.2209+ 0.0036(SE) GMA ASH/GMA 90.2% ANALYZED BY: PWU CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE): CHR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 3/7/75 (HFL) DETAILED RESULTS: 40-004 C10 PU239 (NEW) 780922 239PU (PLUTONIUM) NAME: *Case No.: 40-004 *SAMPLE NO.: EVENT: DEATH/E *DATE OF EVENT: 451003 *LAB No.: 2980 TYPE: BO SAMPLE DESCRIPTION: RIB Item Unit --------ANALYSIS NUMBER--------- 1 2 1. SAMPLE SUB-NUMBER 010E 010D 2. METHOD CRI CRI 3. DATE REQUESTED 770812 770812 4. DATE ANALYZED GMA 770804 780823 5. SAMPLE SIZE 0.109 0.130 6. ALIQUOT (FRACTION) 1.000 1.000 7. SAMPLE SIZE MEASURED GMA 0.109 0.130 8. 242 PU SPIKE DON 42.740 43.770 9. STD. ERROR OF ITEM 8 CTS 0.380 0.290 10. 242 PU SAMPLE COUNTS PCI 25084 10882 11. 239 PU SAMPLE COUNTS PCI 15704 7931 12. 239 PU IN SAMPLE PCI 12.054 14.371 13. STD. ERROR (COUNTS+SYS) PCI 0.163 0.233 14. CONCENTRATION 239 PU PCI/GMA 110.489 110.888 15. STD. ERROR (CNT+SYS) PCI/GMA 1.493 1.794 16. REFERNCES-CHR DOCS. R111RW R111RW *RESULTS: AT TIME OF FIRST MEASUREMENT* 1. PU CONCENTRATION OR RATE (WTD. MEAN) 110.652 PCI/GMA 2. STD. ERROR (EXTERNAL) 0.196 PCI/GMA 3. STD. ERROR (INTERNAL) 1.148 PCI/GMA 4. VARIANCE RATION.F 0.029 5. FRACTIONAL STD. ERROR 0.0104 6. PU (MEAN) IN ALIQU #1 12.072 + 0.125 PCI *RESULTS: AT TIME OF EVENT* PU CONCENTRATION OR RATE: 101.755 + 0.125 PCI/GMA ANALYZED BY:CGC CHECKED: REVIEWED BY/DATE: COMMENTS AND REFERENCES: TO (BY/DATE):REW HR FILE: __SR FORM:_____SA CARD: ____CHEM FILE:____ CHR FORM 10/14/77 (HFL) J. R. Oppenheimer L. H. Hempelmann Health Hazards related to Plutonium A great deal of concern has been expressed during the past two weeks by members of the Chemistry Division about the inability of the Medical Group to detect dangerous amounts of plutonium in the body. This concern was occasioned by the accidental explosion of 10 milligrams of plutonium in Don Wastick's face with the subsequent ingestion of an unknown amount of this material. The questions which have been raised by the chemists are: 1) how much plutonium was absorbed by the gastro-in-testinal tract in this case, 2) what fraction of a serious dose does the absorbed plutonium represent and 3) is it safe for Mastick to go back to work in Building D at his old job. The present medical knowledge of the hazards of plutonium is derived entirely from tracer studies of the metabolism of this element in the rate and from calculation of tissue ionization produced by alpha radiation. Interpretation of Dr. Hamilton's data on rate in terms of humans indicates that 50-100 micrograms of plutonium in the skeletal system is the lethal dose. Calculations of the dangerous dose of plutonium in the lung tissue leads to answers between 0.50-5.0 micrograms depending upon the assumptions which have been made. Dangerous amounts of plutonium in the body should be detectable by finding plutonium in the excreta. If the rate or excretion in man is the same as it is in rats, one would expect to find in the daily output of urine about one ten-thousandth of the amount in the body or 5-10x10-3 micrograms in the case of a lethal amount of plutonium. About five to ten times this amount should be present in the stools each day. One can immediately see the difficulty involved in extracting such small amounts of plutonium from large quantities of excreta. As yet no satisfactory method of assaying excreta has been devised although full time chemist here and another at Chicago have been working on this problem. Concerning the detection of plutonium in the lung, no experimental work has been done although we have some reason to think that enough ion pairs will be present in the expired air to be detectable by suitable ionization chambers. In several discussion with Mr. Kennedy, Mr. Wahl and Mr. Mastick, we have discussed and advisability of giving a higher priority to the medical problems related to plutonium. It would not seem out of place to raise this question now as accidents similar to the one described above are bound to happen again despite the most elaborate precaution. 16 August 1944 J. R. Oppenheimer L.H. Hempelmann Health Hazards related to Plutonium Continued - Page 2 It seemed to us that the following medical problems are the ones to which answers are urgently needed" 1. Development of methods of detection of plutonium in the excreta. 2. Determination of the factor by which the amount of plutonium in the excreta must be multiplied to ascertain the amount in the body. 3. Development of methods of detection of plutonium in the lung. 4. Further and more complete animal experimentation. I should like to discuss this matter with you at greater length. In the meantime, Mr. Mastick has been transferred to my group temporarily by Mr. Kennedy to work on the problems of detection of plutonium in the excreta. cc/ Mr. Kennedy Mr. Wahl File August 16, 1944 L. H. Hempelmann J. R. Oppenheimer Your memorandum of August 16, 1944 In answer to your memorandum on the health hazards of plutonium, and in confirmation of our conversation. I should like herewith to authorize you to undertake two programs: (a) the development of methods of detection of plutonium in the excreta; (b) the development of methods of detection of plutonium in the lung. We both agree that if this program is to be effective it must be prosecuted with rather high priority. We both agree that in view of the many urgent problems facing the laboratory, it should be carried out with as small as investment of personnel as possible. We think that there are good chances that the work can be carried out with fewer than ten people. If the program should threaten to grow beyond this point, I should like to have you clear with me before carrying out such an expansion. As for the biological sides of the work, which may involve animal or even human experimentation, I feel that it is desirable if these can in any way be handled elsewhere not to undertake them here. In any case, problems (a) and (b) above must be solved before the biological findings can be applied, and the methods developed for them may have a real if limited usefulness even in the absence of further biological research. I suggest that you and I discuss the biological questions with Colonel Warren at a very early date. cc: Dr. Bacher Dr. Kennedy University of California January 11, 1945 Proposed Biochemical Program at University of California J.G. Hamilton In this letter I have attempted to give you a survey of future work which I feel can be accomplished at Berkeley. As you will note it is divided into two major categories, namely, the health project efforts, which of course, will remain under the direct supervision of Dr. Stone as it has in the past; and problems relating to the use of the electron. The cyclotron is at the disposal of all interested members of the Metallurgical laboratory and associated projects for aid to them in their various problems. I am of the opinion that the present status of metabolic and toxicity studies with product to date is informative to a considerable degree. However, this information is far from being sufficiently complete to enable those concerned to meet all of the present problems involved in the protection of individuals exposed to product. This aspect of the problem in opinion, became emphasized upon the consideration of the protection of the individual after their exposure to this substance. The phases of experimental efforts with product, most of which I believe to be within the category of research activities useful in winning the war and which we in Berkeley are in a position to render assistance, may be summarized in the following manner: It will be noted that the majority of the different research projects listed below are of such a nature that it is difficult to differentiate between effort that is clearly identified with immediate wartime needs to a program of activity which could be classified as being in the longer range category. I feel that this close relationship between the immediate and longer range phases of our work at Berkeley is advantageous because, first; if the program is either terminated or curtailed at anytime there will be relatively little lost effort, and second; a maximum degree of continuity will exist between the two types of approach to the problems laid out for us here. 1. Further study of the metabolic behavior of product oxide smokes with particular reference to the correlation between particle size and pulmonary retention, and a continuation of the investigation of the rates of elimination of product deposited in the lungs for protracted intervals after exposure ranging up to one year. [not readable] 3. A study of the metabolic properties of product which has been complexed with agents such as citrate, tartrate and exslate, etc. The purpose of this particular effort is to a large degree directed to the development of a method of administering product in such a manner as not to have this substance remain in considerable quantities at the site of injection or to suffer entrapment in organs such as the liver following intravenous injection of inorganic compounds which colloidal at the of the body. I believe that any thoroughly satisfactory toxicity studies must await the development of more suitable methods of administration than are now available and the use of complexes would appear to posses a fair possibility of success in this direction. This phase of the program is already under way at Berkeley with investigation of five different complexes. 4. It is planned here at Berkeley to undertake, on a limited scale, a series of metabolic studies with product using human subjects. This part of our program is awaiting the development of a more satisfactory method of administration of product than is now available. It is hoped that the results of the studies with the complexes will enable us to go ahead with this phase of our work. 5. We expect to initiate a limited number of toxicity experiments using 48 rather than 49 to rule out any question of chemical toxicity which is felt may be present in certain experiments using the heavier isotope of product. The 48 is to be produced by 50 cyclotron for this purpose and even though both isotopes are produced by the deuteron bombardment of tuballoy the specific activity of this mixture ranges from 40 to 100 fold that of pure 49. If we are successful in producing 48 by proton bombardment with the 60" cyclotron the specific activity for the 48 will be approximately 400 times that of 49. These studies are of necessity-limited to a relatively restricted number of small animals such as rats and mice due to the rather low yields of 48 produced by the cyclotron. 6. I believe that a few tracer studies both with human subjects and animals using 48 should be made in as much as it seems desirable that the metabolic behavior of product should be studied using concentrations in the body of the order of 1/100th of a microgram per kilo of body weight. Due to the much lower specific activity of 49 as compared to 48, accurate tracer studies using 49 and with this range of concentration in the body are rendered most difficult. It is entirely possibly that significant differences in the metabolic properties of product might exist in the range of 1/100th micrograms per kilo of body weight as compared to the usual tracer studies with 49 in which the concentrations employed for administration is of the order of 25 to 100 micrograms per kilo of body weight. This phase of the problem I believe deserves attention since it is the range from 1/100th to 1/10th of a microgram per kil of body weight which is of greatest concern from the point of view of exposure to personnel. the decontamination studies which are directed towards the goal for [not readable] methods for either the acceleration of excretion of product deposited body or its translocation to less radio-sensitive regions is a phase of effort which I feel is of importance and should be continued. This problem nature long range in character and one from which results of positive ____ value cannot be anticipated immediately. In fact it is entirely possible only a very limited degree of success may be achieved. An example of unsuccessful realization of such a goal can be cited in the unfortunate state the problem of radium poisoning. In should be noted in passing that work of this character has been in progress at Berkeley for six months. 8. Radio-autographic studies of appropriate tissues are to be made as a aid to the different programs noted above. It is felt that they will shed additional information upon the question in hand. The value of this technique has already demonstrated its usefulness as an experimental tool. 9. An investigation of the fixation of product by soils, upon buildings, concrete structure, reservoirs, etc. would seem to merit some attention in the future. In addition, the uptake of product from soils by plants seems worthy of some investigation and could well be included in a basic research program after the war. Even though considerable information has been acquired concerning the general metabolic characteristics of the major members of the fission products possession [not readable] concerning these substances that is of interest to the immediate war effort. [not readable] in the following list of problems are several research projects that can be identified with longer range developments for the future. 1. Considerable information has already been acquired concerning the behavior of fission products when distributed in the air in the form of a smoke of U308 produced by burning tuballoy rods whose radioactive composition approximated that of the average Clinton slug. However, in view of the fact that this material is now becoming available with a much higher specific activity it would appear desirable to study the behavior in the body of such smokers at a much higher specific activity. It is planned shortly to initiate exposures of rate to product oxide smoke in which the fission product activity is of the order of 1000 fold that of the average material from the Clinton unit. This type of research effort has in mind the simulation on an extremely small scale either a destructive fire at Hanford or an accidental explosion at Y. 2. The distribution in the body of fission products following inhalation as a spary or dust of water soluble compounds would seem to be worthy of devoting some effort by our group here at Berkeley on the basis for a project to be classified as not being identified as urgent in winning the war. 3. The metabolic properties of fission products either possessing relatively short half-lives or of low abundance should be undertaken in the future. This type of effort I believe can be identified with longer range. equipment projects. Radio-clements in this category include Se, Mo, Rh, Pd, Ag, Cd, Sn, Sb, Md, 61, and Eu. This project would be learned closely after the procedures employed for the fission products ready studied. It should be noted in passing that the production and lation of most of these minor members of the fission group in the prior free form could be best accomplished with the aid of the 60" cyclotron. 4. The study of the fixation of fission products in soils is now well [not readable] way with the view of aiding the problem of waste disposal at Hanford in Clinton. It includes an attempt to estimate the hazards that may be expected to arise from the accidental or intentional release to the soil fission products. Included in this program is the investigation of the absorption of individual radioelement of the major members of the long life fission group in tracer amounts in a selected group of soil clays. A measure of degree of removal of fission activity from the waste soils perculated in the degree of removal of fission activity from the waste soils perculated through beds of typical Hanford soil samples is being made at present as well as the migration of radioactive tracers in such soils. In order to investigate the possibility of decontamination of active soils, teaching and exchange experiments are to be carried out at some time in the near future. 5. The study of the fixation of fission products in building materials. This is to include measurements of the degree of fixation of radioelement on the surfaces of concrete structures such as reservoirs, etc. wooden building materials and a number of miscellaneous substances such as rubber, glass, metals, plastics, etc. Special attention will be paid to the problem of decontamination of these materials. 6. The study of the agricultural hazards resulting from the absorption of fission products by plants. Measurements of the degree of uptake of radioelement by agricultural plants from active soils is not being carried out in the laboratory and in the greenhouse. The distribution of the absorbed activity within the plant is also being investigated. 7. Fundamental and long-range studies of the chemical factors involved in the absorption of trace elements on clay minerals can be considered as being a part of the plan for future work. Information regarding the absorption of polyvalent ions either in macro, or micro amounts is virtually non-existent. 8. A detailed study of the chemical factors involved in the fixation and absorption of trace elements by plant roots. The technique of preparing radio-autographs will be of considerable aid in this problem. 9. Immobilizing of agricultural lands by the use of fission products. 10. It would appear, in my estimation, of value to consider the therapeutic possibilities of several of the long-life fission products for the treatment of malignant conditions. It might be noted in passing that two of the long-life fission products have already demonstrated that they are of therapeutic value, namely, radio-strontium in the treatment of certain types of bone cancers, and radio-iodine for the treatment of hyperthyroidism. [not readable] not devoted much space in the above discussion concerning fission [not readable] to the question of the military use of these substances. Actually the results in hand and these anticipated in the near future can be assembled and interpreted to answer many of the problems that might be expected to arise of such military issues ever present themselves. Moreover, the planning of our fission product work both with the smokes and soil studies has always kept the military aspects in mind. If we were directed tomorrow to reorganize our fission product work to the military needs of radioactive warfare almost all of our past and present efforts with fission products would be directly applicable. The overall period for the 60" cyclotron has unfortunately been prolonged by several technical difficulties. However, we achieved resonance with deuterons at a calculated energy of 23.5 mev three weeks ago. It present the necessary adjustments and trouble shooting is under way to permit us to increase the efficiency to the point where effective and routing bombardment of samples for the Metallurgical Laboratory, site, the Rochester group, and Dr. Latimer's section can be initiated. This achievement should be accomplished with the next few weeks. I have indicated below some of the immediate duties to be performed by the instrument as well as some longer range projects for the future. Obviously there are many other experimental problems for which the cyclotron can be of use but since I am not a physicist I am certain that the following items do not cover other important research problems in this direction. 1. At present one of the most effective uses of the 60" cyclotron appear, from discussions I have had with various members of the Metallurgical Laboratory and in particular Dr. [not readable] Many of these isotopes, notably elements 95 and 96, as well as the lighter isotopes of tuballoy, Neptunium and product presumably could only be produced by cyclotron bombardment if they exist. Others such as PU 240, 241 could be produced with relatively small amounts of PU 239, which would considerably simplify many of the investigations it would be desirable to make with these various elements. The amounts produced, of course, would presumably range from 1/10th of a microgram to 100 micrograms but it is my understanding that these amounts would be adequate for purposes such as determination of the character of radiation, rates of spontaneous fission and a study of the chemical properties of 95 and 96. 2. The license of energy from 16 mev and 32 mev for deuterons and alpha particles respectively to 23.5mev and 47mev will provide us with a source of faster neutrons than were heretofore available. I have found that several members of the Metallurgical Laboratory, notably Dr. Burton and Dr. Frank, have shown a lively interest in the use of these high energy neutrons for the [not readable] of their interaction with such materials as graphite, Be, aluminum, etc. might be noted in passing that due to the manner in which the external beam is focused, a small area of very high fast neutron intensity is present just is focused, a small area of very high fast neutron intensity is present just adjacent to the target material. Measurements which have been made at various times by different individuals at Berkeley indicate a fast neutron flux of the order of 1012 neutrons per second per square centimeter when beryllium is bombarded with 200/uc of 16 mev deuterons. Another possible useful role that these fast neutrons may perform is their application for studying isotopes [not readable]. It is possible that these fast neutrons can be employed for the purpose of bombardment which would be of aid for the identification of certain members of fission group. 3. The availability of more energetic deuterons and alpha particles will be possible reactions such as the d-alpha type which should also prove of value or purposes of cross bombardment as an aid in identifying various members of the fission group. 4. It is my impression that biological studies concerning the relationship between neutrons of various energies and their relative biological effects would be of interest to various members of the health group. The problem ____ not be of immediate importance but it would be worthy of consideration for experimental investigation in the future. 5. A very pressing and immediate use of the instrument is the preparation of U232 and PU238. These two isotopes are of current and practical usefulness to both the chemists and biologists. 6. The availability of the 60" cyclotron to both the health group at Berkeley and to Professor Latimer's group has proven in the past to be of considerable assistance and is sure to continue to be in the future. Examples are the production of 48 for tracer work and toxicity studies with product for the health group and the preparation of some of the short lived fission products and NP239 for Dr. Latimer's group. 7. For the future there is the very interesting possibility of studying nuclear reactions produced by the acceleration of nuclei of substance such as Be3, Be9, C12, N14, O16. In the case of 016 the accelerated particles would have in approximate energy of 200 mev in the 60" cyclotron. This of necessity would require considerable development of a new type of ion source to make possible the production of a sufficient number of stripped atoms to be usable. I might note in passing that Lithium and Boron were intentionally omitted from the list because the presence of these two elements, and in particular Lithium, in the vacuum chamber of the cyclotron would after a short time render operation difficult if not impossible until the apparatus has been thoroughly cleaned. In addition, of course, the possibility of producing protons up to 20 mev and deuterons to 40 mev and alpha particles to 80mev exists although here again the successful achievement of this feat would presumably require the expenditure of considerable time and effort and should be considered in the category of future development. I trust that the above information will serve as an indication of the nature of our various present and future enterprises at the Crocker Laboratory. The staff of the biological group is equivalent to twelve full time workers which includes a secretary and guard. The cyclotron staff is compromised of 14 full time people whose number will be reduced to an operating crew of 10 when our present period of tuning up and adjusting is completed. J.G. Hamilton, M. D. J. R. Oppenheimer J. W. Kennedy, A. C. Wahl, J. F. Nolan, Capt. M. C. Wright Langham, L. H. Hempelmann Medical Research of Manhattan District concerned with Plutonium At a joint meeting of representatives of the CM division and the medical group on 10 March 1945, it was agreed that the director should be asked to submit a request to the Manhattan district for an intense medical research program to be concerned with the detoxification of persons poisoned with plutonium. AS far as is known to us, only two people of the several hundred engaged in medical research by the Manhattan district are concerned with this problem and these two are working only on a part time basis. In view of the large numbers of people on this project exposed to extremely great quantities of plutonium, it would seem imperative that an intensive study of the treatment of plutonium poisoning be undertaken as soon as possible. It was also pointed out at this meeting that the very important and difficult problem of detection of alpha active material in the lungs has been studied only at this project and here only on a very limited scale. It was felt that this problem should be given much higher priority here and at other projects. It is suggested that our relationship to the medical program of the Manhattan district be discussed with Colonel Warren on his visit here 19 March 1945. LHH/Fw cc/ J. W. Kennedy ______________ A. C. Wahl J. W. Kennedy Capt. J. Nolan Wright Langham L. H. Hempelmann ______________ A. C. Wahl ____________________ Capt. J. Nolan ____________________ Wright Langham ____________________ L. H. Hempelmann 29 August 1944 To: J. R. Oppenheimer FROM: L. H. Hempelmann SUBJECT: Medical Research Program Colonel Warren has suggested that I summarize the biological research program which was agreed upon in our conference with you and Mr. Kennedy on 25 August 1944. This program which will be pursued with a relatively high priority will consist of three parts: 1. The development of chemical methods of determining plutonium in the excreta and in tissues and of ionization methods of detecting plutonium in the lungs. 2. Animal experimentation to check the methods described above. 3. Tracer experiments on humans to determine the percentage of plutonium excreted daily. When satisfactory analytical methods have been developed in this laboratory the problem of carrying out further metabolic studies will be turned over to another medical group, presumably the Rochester group. It was also decided that the Rochester group should undertake a series of experiments with plutonium supplied by this project to determine the lethal dose in animals. It is felt that a temporary staff of ten or eleven people will be required to complete the above program within a reasonable period of time. This will include four chemists, four chemical technicians, one physicist and two unskilled laboratory assistants. Of these, it is probable that one chemist and two or three technicians will remain permanently with the Medical Group to test for plutonium in the excreta of the working personnel. Only the physicist and two technicians are needed to complete the proposed temporary staff; arrangements have been made to secure these people. It is planned to have the activities of the above group supervised by an advisory committee representing the chemistry, physics and medical divisions. Considerable additional laboratory space will be needed for this program. This will amount to about 1500 square feet, the approximate size of the Q building. If the Q building can be obtained, this will allow us to have a room to house the animals and carry out dirty operations (ashing and drying of tissues, etc.) and another for electronics. 29 August 1944 TO: J. R. Oppenheimer FROM: L. H. Hempelmann SUBJECT: Medical Research Program Page 2-Continued It will also be necessary for us to have a "counting shack" outside the Technical Area as we will be concerned with the detection of very shall amounts of radioactivity. It is proposed that the present hematology laboratory (U-1) and the medical office be retained at least until the temporary program has been completed. It is hoped that with the personnel and facilities outlined above the program can be completed in four months. 26 March, 1945 TO: Mr. R. J. Oppenheimer FROM: Dr. L. H. Hempelmann SUBJECT: Meeting of Chemistry Division and Medical Group On Friday 23 March, 1945, representatives of the Chemistry Division and Medical Group met with Lt. Colonel Hymer Friedell to discuss the medical problems of this project and their relationship to the Medical Research Program of the Manhattan District. The need for further study of diagnostic procedures and for a detoxification program was considered and thought to be urgent. It was agreed that the Medical program concerned with the toxicity of plutonium should be pursued with the following priorities: a. Improvements of methods for protection of personnel from exposure to plutonium. b. Development of methods for diagnosis of overexposure of personnel. c. Study of methods of therapeusis for overexposed personnel. The following requests were submitted by this group to Colonel Friedell for consideration by the Medical Section of the Manhattan District. 1. Continued support of present studies of methods of assaying excreta for plutonium. The Manhattan District is asked to help make arrangements for a human tracer experiment to determine the percentage of plutonium excreted daily in the urine and faces. It is suggested that a hospital patient at either Rochester or Chicago be chosen for injection of from one to ten micrograms of material and that the excreta be sent to this laboratory for analysis. 2. Development of methods for detection of Plutonium in the lungs. This will include, 1) the development by this laboratory of a method of assaying expired air for ionization and 2) animal studies at other laboratories to determine absorption from the lung of plutonium compounds used in large quantities at this laboratory. 3. Intensification of the detoxification program in line with the priorities established above. 4. A more satisfactory relationship of this project with the Medical Program of the Manhattan District that the facilities of the Manhattan District be available for the solution of our problems. It is suggested that channels established through which our problems can be brought to the attention of those individuals who plan the research program of the Manhattan District. L. H. Hempelmann cc: Col. Warren J. W. Kennedy Lt. Col. Friedell A. C. Wahl W. Langham File March 29, 1945 Colonel S. L. Warren, P.O. Box E, Oak Ridge, Tennessee Dear Colonel Warren: We are enclosing a record of discussions held here a few days ago during the visit of Colonel Friedell. We had hoped that you might be with us at the time, and we were sorry that ill health prevented this. I should like to add my personal indorsement to the requests outlined in the accompanying memorandum. We all have the feeling that at the present time the hazards of workers at Site Y are probably very much more serious than those at any other branch of the Project, and that it would be appropriate that the medical program of the Manhattan District consider some of our problems rather more intensively than they have in the past. I think that you yourself know the reason for some of these hazards, and we tried to give Colonel Freidell a picture of them. I believe that the order of priority outlines in the accompanying memorandum is a wise one. Although we would have some ideas of how to pursue all of the topics mentioned, we have, as you know, neither the personnel nor the facilities which would be involved in this. It was our impression that if other workers on the medical program were better informed about what was important from our point of view they would probably be glad to help us out. Certainly we will appreciate any help that you can give us. Sincerely, J. R. Oppenheimer atw Incl: memo 2/36/45 cc: Lt. Col. Friedell Dr. L. Hempelmann